Intramolecular Alkene Carboamination Reactions for the Synthesis of Enantiomerically Enriched Tropane

ORGANIC LETTERS

2011 Vol. 13, No. 11 2962–2965

Danielle M. Schultz and John P. Wolfe*

Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109-1055, United States

jpwolfe@umich.edu

Derivatives

Received April 20, 2011

ABSTRACT

The synthesis of tropane derivatives via intramolecular Pd-catalyzed alkene difunctionalization reactions is described. Enantiopure N-aryl- γ -aminoalkenes bearing an aryl or alkenyl halide adjacent to the amino group were converted to benzo- or cycloalkenyl-fused tropane products in good yield and with no loss of enantiopurity.

The azabicyclic framework is widespread in both natural products and pharmaceutical targets that have a range of central nervous system (CNS) activities including anticholinergic, sedatory, and cognitive. Benzo-fused tropanes are an interesting and important subclass of azabicycloalkanes. These ring systems are displayed in numerous drug leads and pharmaceuticals including 1, which has been studied for the treatment of Type 2 diabetes, and 2, which is an antitumor drug candidate (Figure 1). MK-801

(dizocilipine), a related heterocycle bearing two fused aryl rings, has exhibited anticonvulsant activity^{4a} and has also been used in animal models of schizophrenia.^{4b}

Figure 1. Biologically active benzo-fused tropanes.

The medicinal relevance of azabicycloalkanes has stimulated considerable interest among synthetic chemists,

⁽¹⁾ Grynkiewicz, G.; Gadzikowska, M. Pharmacol. Rep. 2008, 60, 439.

⁽²⁾ Ammenn, J.; Paal, M.; Ruehter, G.; Schotten, T.; Stenzel, W. PCT Int. Appl. WO 2000078724, 2000.

⁽³⁾ Ahmed, G.; Bohnstedt, A.; Breslin, H. J.; Burke, J.; Curry, M. A.; Diebold, J. L.; Dorsey, B.; Dugan, B. J.; Feng, D.; Gingrich, D. E.; Guo, T.; Ho, K. -K.; Learn, K. S.; Lisko, J. G.; Liu, R. -Q.; Mesaros, E. F.; Milkiewicz, K.; Ott, G. R.; Parrish, J.; Theroff, J. P.; Thieu, T. V.; Tripathy, R.; Underiner, T. L.; Wagner, J. C.; Weinberg, L.; Wells, G. J.; You, M.; Zificsak, C. A. PCT Int. Appl. WO 2008051547, 2008.

^{(4) (}a) Thompson, W. J.; Anderson, P. S.; Britcher, S. F.; Lyle, T. A.; Thies, J. E.; Magill, C. A.; Varga, S. L.; Schwering, J. E.; Lyle, P. A.; Christy, M. E.; Evans, B. E.; Colton, C. D.; Holloway, M. K.; Springer, J. P.; Hirschfield, J. M.; Ball, R. G.; Amato, J. S.; Larsen, R. D.; Wong, E. H. F.; Kemp, J. A.; Tricklebank, M. D.; Singh, L.; Oles, R.; Priestly, T.; Marshall, G. R.; Knight, A. R.; Middlemiss, D. N.; Woodruff, G. N.; Iversen, L. L. J. Med. Chem. 1990, 33, 789. (b) Rung, J. P.; Carlsson, A.; Markinhuhta, K. R.; Carlsson, M. L. Prog. Neuro-psychopharmacol. Biol. Psych. 2005, 29, 827.

⁽⁵⁾ For a recent review, see: Pollini, G. P.; Benetti, S.; De Risi, C.; Zanirato, V. Chem. Rev. 2006, 106, 2434.

⁽⁶⁾ For selected recent examples, see: (a) Lin, G. -J.; Zheng, X.; Huang, P. -Q. Chem. Commun. 2011, 47, 1545. (b) Davis, F. A.; Theddu, N.; Edupuganti, R. Org. Lett. 2010, 12, 4118. (c) Reddy, R. P.; Davies, H. M. L. J. Am. Chem. Soc. 2007, 129, 10312 and references cited therein. (d) Shing, T. K. M.; Wong, W. F.; Ikeno, T.; Yamada, T. Org. Lett. 2007, 9, 207. (e) Martin, S. F. Pure Appl. Chem. 2005, 77, 1207. (f) Mans, D. M.; Pearson, W. H. Org. Lett. 2004, 6, 3305 and references cited therein. (g) Mikami, K.; Ohmura, H. Chem. Commun. 2002, 2626.

and a great number of methods have been developed for the construction of saturated frameworks. $^{5-7}$ In contrast, only a handful of routes have previously been developed for the synthesis of benzo-fused tropane scaffolds. $^{8-12}$ We envisioned that an intramolecular Pd-catalyzed carboamination reaction 13,14 of a γ -aminoalkene substrate such as **4**, which contains a 2-bromoaryl (or 2-bromoalkenyl) group adjacent to the amino moiety, could provide a complementary approach to the benzo-tropane framework **3** (Scheme 1). This transformation would generate two bonds and 1-2 stereocenters (at C8 and C9) in a controlled fashion, and the requisite substrates could be prepared in enantiopure form via addition of unsaturated Grignard reagents **6** to readily available chiral imines **5**.

Scheme 1. Intramolecular Carboamination Strategy for the Synthesis of Benzo-Fused Tropane Derivatives

$$\begin{array}{c} \stackrel{\text{N.PG}}{\longrightarrow} \stackrel{\text{N.PG}}{\longrightarrow} \\ \stackrel{\text{N.PG}}{\longrightarrow} \stackrel{\text{N.R*}}{\longrightarrow} \\ \stackrel{\text{MgBr}}{\longrightarrow} \\ \stackrel{\text{MgBr}}{$$

The enantioenriched substrates 4 required for the strategy outlined above were synthesized in four steps from readily accessible o-bromobenzaldehydes or β -bromo- α , β -unsaturated aldehydes (Scheme 2). Specifically, condensation of an appropriate bromoaldehyde with (R_S) -(+)-tert-butanesulfinamide¹⁵ afforded aldimine 7 as a single enantiomer. Subsequent 1,2-addition of a homoallylic Grignard reagent to 7 afforded N-tert-butanesulfinyl

amines **8**. ¹⁶ The Grignard addition reactions typically proceeded with 4–13:1 dr, but after flash chromatography the desired amine products were obtained with a high degree of stereochemical purity in moderate to good yields (51–76%). In the few instances when the diastereoselectivity of the Grignard addition to the aldimine was poor (2–3:1), lower yields (38–46%) of amine products were obtained after separation of the stereoisomers. Acid-mediated cleavage of the chiral auxiliary to give primary amines **9**, followed by a Pd/Xantphos-catalyzed *N*-arylation¹⁷ with bromobenzene, afforded desired *N*-phenyl-γ-aminoalkene substrates **4a**–**h** in good yield. Although these conditions usually provided good chemoselectivity for the desired *N*-arylation, in a few instances competing 2-benzyl pyrrolidine formation occurred, which led to modest yields.

Scheme 2. Synthesis of Tropane Substrates^a

^a Overall yields of **4a**-**h** over four steps: **4a**, 20%; **4b**, 36%; **4c**, 27%; **4d**, 14%; **4e**, 41%; **4f**, 31%; **4g**, 39%; **4h**, 41%.

Our prior studies on Pd-catalyzed carboamination reactions that yield substituted pyrrolidines suggested the conversion of 4 to 3 was likely to occur via a key intramolecular aminopalladation of an intermediate Pd(aryl)-(amido) complex such as 10 (Scheme 3). 13,14 The general feasibility of this process was supported by prior studies in our lab, which illustrated that intramolecular carboaminations of substrates such as 11 effectively generated pyrrolidines bearing attached carbocyclic rings (e.g., 13). 18 This latter transformation is believed to proceed via intramolecular (transannular) insertion of the alkene into macrocyclic Pd(aryl)(amido) complex 12, which bears a single phosphine ligand. 19 As such, we elected to examine catalysts supported by monodentate phosphines in our initial optimization experiments.

Org. Lett., Vol. 13, No. 11, 2011

⁽⁷⁾ For pioneering studies, see: (a) Robinson, R. J. Chem. Soc. Trans. **1917**, 111, 762. (b) Willstätter, R.; Wolfes, O.; Mader, H. Liebigs Ann. Chem. **1923**, 434, 111. (c) Schopf, C.; Lehman, G. Liebigs Ann. Chem. **1935**, 518, 1

⁽⁸⁾ For radical cyclization approaches, see: (a) Funabashi, K.; Ratni, H.; Kanai, M.; Shibasaki, M. *J. Am. Chem. Soc.* **2001**, *123*, 10784. (b) Ikeda, M.; Hamada, M.; El Bialy, S. A. A.; Matsui, K.; Kawakami, S.; Nakano, Y.; Bayomi, S. M. M.; Sato, T. *Heterocycles* **2000**, *52*, 571.

⁽⁹⁾ For approaches involving Diels—Alder reactions, see: (a) Constable, K. P.; Blough, B. E.; Carroll, F. I. *Chem. Commun.* **1996**, 717. (b) Grunewald, G. L.; Sall, D. J.; Monn, J. A. *J. Med. Chem.* **1988**, *31*, 433.

⁽¹⁰⁾ For [3 + 2] cycloaddition approaches, see: (a) Xing, S.; Pan, W.; Liu, C.; Ren, J.; Wang, Z. Angew. Chem., Int. Ed. 2010, 49, 3215. (b) Grigg, R.; Somasunderam, A.; Sridharan, V.; Keep, A. Synlett 2009, 97. (c) Yeom, H.-S.; Lee, J.-E.; Shin, S. Angew. Chem., Int. Ed. 2008, 47, 7040. (d) Padwa, A.; Dean, D. C.; Osterhout, M. H.; Precedo, L.; Semones, M. A. J. Org. Chem. 1994, 59, 5347.

⁽¹¹⁾ For an approach involving Pd-catalyzed allylic alkylation, see: Li, Q.; Jiang, X.; Fu, C.; Ma, S. Org. Lett. 2011, 13, 466.

⁽¹²⁾ For a hydroamination approach, see: Molander, G. A.; Dowdy, E. D. *J. Org. Chem.* **1999**, *64*, 6515.

⁽¹³⁾ For reviews, see: (a) Wolfe, J. P. Eur. J. Org. Chem. **2007**, 571. (b) Wolfe, J. P. Synlett **2008**, 2913.

^{(14) (}a) Ney, J. E.; Wolfe, J. P. *Angew. Chem., Int. Ed.* **2004**, *43*, 3605. (b) Bertrand, M. B.; Neukom, J. D.; Wolfe, J. P. *J. Org. Chem.* **2008**, *73*, 8851. (c) Lemen, G. S.; Wolfe, J. P. *Org. Lett.* **2010**, *12*, 2322.

⁽¹⁵⁾ Robak, M. T.; Herbage, M. A.; Ellman, J. A. Chem. Rev. 2010, 110, 3600.

⁽¹⁶⁾ Efforts to prepare substrates bearing quaternary stereocenters adjacent to the amino group were unsuccessful due to the low reactivity of *N*-sulfinyl ketimines towards organometallic nucleophiles.

^{(17) (}a) Yang, B. H.; Buchwald, S. L. *Org. Lett.* **1999**, *1*, 35. (b) Janey, J. M. In *Name Reactions for Functional Group Transformations*; Li, J. J., Ed.; John Wiley & Sons: Hoboken, NJ, 2007; pp 566–611.

⁽¹⁸⁾ Nakhla, J. S.; Kampf, J. W.; Wolfe, J. P. J. Am. Chem. Soc. 2006, 128, 2893.

⁽¹⁹⁾ Recent mechanistic studies also suggest that alkene aminopalladation occurs most rapidly from palladium complexes bearing one phosphine ligand. See: (a) Neukom, J. D.; Perch, N. S.; Wolfe, J. P. Organometallics 2011, 30, 1269. (b) Neukom, J. D.; Perch, N. S.; Wolfe, J. P. J. Am. Chem. Soc. 2010, 132, 6276. (c) Hanley, P. S.; Markovic, D.; Hartwig, J. F. J. Am. Chem. Soc. 2010, 132, 6302.

Scheme 3. Intramolecular Carboamination Mechanism

The optimization of conditions for the tropane-forming reactions was explored using substrate 4a (Table 1). Our optimization studies focused on the phosphine ligand structure, using otherwise standard conditions known to give satisfactory results in most carboamination reactions (NaO^tBu, toluene, 90–110 °C). Use of P(o-tol)₃ as the ligand led to incomplete conversion of the starting material and only afforded small quantities of the desired tropane product. Improved results were obtained with the bulky electron-rich DavePhos^{20a} ligand, but the reaction still failed to reach completion. However, use of the slightly smaller electron-rich ligand PCy₃²¹ led to complete consumption of the starting material and provided 14 in 77% isolated yield (entry 4). Finally, to probe the hypothesis that the key intermediate bears a single phosphine ligand, the efficacy of the bidentate ligand dppf was examined. As postulated, poor conversion of the starting material occurred and only a low yield of 14 was obtained (entry 5).

Table 1. Optimization of Reaction Conditions^a

| entry | ligand | conversion (%) | yield of 14 (%) |
|-------|-----------------------|----------------|------------------------|
| 1 | P(o-tol) ₃ | 59 | 21 |
| 2 | $P(p-F-C_6H_4)_3$ | 100 | 69 |
| 3 | DavePhos | 76 | 40 |
| 4 | PCy3•HBF4 | 100 | 80 $(77)^c$ |
| 5 | dppf | 35 | 11 |

^a Conditions: 1.0 equiv of **4a**, 2.0 equiv of NaO'Bu, 2 mol % Pd₂(dba)₃, 8 mol % ligand (4 mol % of dppf was used for the experiment shown in entry 5), toluene (0.1 M), 95 °C, 14 h. ^b Yields were determined by ¹H NMR analysis of crude reaction mixtures that contained phenanthrene as an internal standard. ^c Isolated yield (average of two experiments).

With optimized reaction conditions in hand, the scope and limitations of the intramolecular carboamination reactions were explored. Overall these transformations proved to be quite general and afforded various tropane derivatives in good yields and with no loss of enantiopurity (Table 2). The presence of a methylenedioxy group on the aryl bromide was tolerated (entry 3), and the heteroarylfused tropane 17 was generated from pyridine derivative 4d in good yield. Cyclic alkenyl halides were also viable

Table 2. Pd-Catalyzed Synthesis of Tropanes^a

$$R = \underbrace{\begin{array}{c} \text{NHPh} \\ \text{I*} \\ \text{Br} \\ \text{R}_1 \end{array}}_{\text{R}_1} \underbrace{\begin{array}{c} 2 \text{ mol } \% \text{ Pd}_2(\text{dba})_3 \\ 8 \text{ mol } \% \text{ PCV}_3 \bullet \text{HBF}_4 \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_2} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{R}_2 \\ \text{R}_3 \\ \text{R}_3 \end{array}}_{\text{R}_1} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_2} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text{NaO'Bu, Toluene, } 95 \, ^{\circ}\text{C} \end{array}}_{\text{R}_3} \underbrace{\begin{array}{c} \text{NNPh} \\ \text$$

| entr | y substrate | product | yield (%) ^b | ee (%) ^c |
|------|-----------------------------|-------------|------------------------|---------------------|
| 1 | NHPh Ha Br | N, Ph | 77% | 97% |
| 2 | NHPh 4b Br | 14 N. Ph | 80% | 98% |
| 3 | NHPh O Br | 0 N.Ph | 82% | 98% |
| 4 | NHPh CH ₃ | N. Ph | 81% | 99% |
| 5 | NHPh | N.Ph | 73% | 92% |
| 6 | 4e NHPh Br CH ₃ | 18 N. Ph | 73% | 93% |
| 7 | NHPh Br Et | N. Ph | 77% ^d | 98% |
| 8 | NHPh Br Et | 21 H Et | 72% ^d | 95% |

^a Conditions: 1 equiv of amine, 1.5 equiv of NaO^tBu, 2 mol % Pd₂(dba)₃, 8 mol % PCy₃•HBF₄, toluene (0.1 M), 95 °C, 10 h. ^b Isolated yield (average of two experiments). ^c No racemization of the substrates occurred during the transformation; the enantiopurities of the starting materials were within 1% ee of the tropane products as determined by chiral HPLC analysis. ^dThe reaction was conducted at 125 °C using 8 mol % of PPh₂Cy as the ligand.

2964 Org. Lett., Vol. 13, No. 11, 2011

⁽²⁰⁾ Ligand definitions: (a) DavePhos = 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)-biphenyl. (b) S-Phos = 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl.

⁽²¹⁾ This ligand was employed as the air-stable tetrafluoroborate salt, which was obtained from commercial sources.

substrates, as **4e**—**f** were efficiently transformed to unsaturated tropanes **18**—**19** (entries 5 and 6, respectively). Unfortunately, efforts to transform noncyclic alkenyl halide substrates into tropane products were unsuccessful, as alkene isomerization and substrate decomposition occurred more rapidly than tropane formation.

The method is also amenable to the generation of quaternary stereocenters, as seen in the conversion of 1,1-disubstituted alkene substrates **4c** and **4f** to **16** and **19**, respectively. The stereospecific conversion of *E*- and *Z*-alkene substrates **4g** and **4h** proceeded smoothly to provide disubstituted tropane products **20** and **21**. In these latter transformations, use of the slightly smaller ligand PPh₂Cy provided better results than our standard Pd/PCy₃ catalyst system. Styrene-derived substrate **4b** smoothly underwent the intramolecular carboamination reaction to yield dibenzotropane **15** in good yield.

Scheme 4. Pd-Catalyzed Synthesis of NMDA Antagonist 24

To further demonstrate the utility of this method, we sought to prepare the MK-801 analog **24** (Scheme 4). This compound has served as a common intermediate en route to MK-801 and derivatives and also exhibits modest NMDA antagonist activity. The synthesis of **24** has previously been accomplished via base-mediated transannular hydroamination of an amino alkene. This route afforded (±)-**24** in three steps from commercially available material. Although this is an effective approach to the racemate, an analogous route to enantioenriched samples of **24** has not been developed. An analogous route to enantioenriched samples

In our synthesis of **24** we sought to effect the carboamination of a substrate related to diphenylmethylamine derivative **4b**, but with a cleavable group on the nitrogen atom in

place of the N-phenyl substituent. Initial efforts to employ N-Boc-protected variants of 4b were unsuccessful and led to either low conversion or decomposition of the starting material. As such, an N-PMP group was selected as the amine substituent, as this aryl protecting group can be cleaved under oxidizing conditions. The requisite substrate 22 was prepared in three steps and with 37% overall yield from o-chlorobenzaldehyde using the route described above in Scheme 2.25 The Pd₂(dba)₃/PCy₃•HBF₄ catalyst was not sufficiently reactive to promote complete conversion of 22 to 23, and a significant amount of unreacted starting material was recovered. However, we were gratified to find that S-Phos, ^{20b} an electron-rich ligand recently shown to be effective in intermolecular carboamination reactions between aryl chlorides and N-substituted- γ -amino alkenes, ²⁶ led to complete substrate conversion. These conditions provided desired tropane 23 in excellent yield and with no loss of enantiopurity. Treatment of 23 with CAN in aqueous acetonitrile at 0 °C led to clean removal of the PMP group and provided 24 in 74% yield.

In conclusion, we have developed a new method for the synthesis of benzo-fused tropanes via an intramolecular Pd-catalyzed alkene carboamination reaction. This method allows for straightforward preparation of *N*-aryl benzotropanes bearing substituents at C8, C9, or on the fused arene ring. In addition, *N*-H tropanes can be accessed through deprotection of *N*-PMP derivatives. Further studies on the application of this method to the construction of complex tropane alkaloids are currently underway.

Acknowledgment. The authors acknowledge the NIH-NIGMS for financial support of this work. Additional funding was provided by GlaxoSmithKline, Amgen, and Eli Lilly. D.M.S. acknowledges the ACS Division of Organic Chemistry for a graduate fellowship and the University of Michigan for a Rackham predoctoral fellowship.

Supporting Information Available. Experimental procedures, characterization data for all new compounds, descriptions of stereochemical assignments with supporting structural data, and copies of ¹H and ¹³C NMR spectra for all new compounds reported in the text. This material is available free of charge via the Internet at http://pubs.acs.org.

Org. Lett., Vol. 13, No. 11, 2011

^{(22) (}a) Monn, J. A.; Rice, K. C. *Tetrahedron Lett.* **1989**, *30*, 911. (b) Monn, J. A.; Thurkauf, A.; Mattson, M. V.; Jacobson, A. E.; Rice, K. C. *J. Med. Chem.* **1990**, *33*, 1069.

⁽²³⁾ Lamanec, T. R.; Bender, D. R.; DeMarco, A. M.; Karady, S.; Reamer, R. A.; Weinstock, L. M. J. Org. Chem. 1988, 53, 1768.

⁽²⁴⁾ Enantiopure samples of **24** have previously been generated via resolution of the racemate. See ref 4a.

⁽²⁵⁾ Initial efforts to use 2-bromobenzaldehyde for the construction of the aryl bromide analog of **22** were unsuccessful, as *N*-arylation of the primary diarylmethylamine with 4-bromoanisole suffered from a competing intramolecular Heck reaction of the bromoalkene.

⁽²⁶⁾ Rosen, B. R.; Ney, J. E.; Wolfe, J. P. J. Org. Chem. 2010, 75, 2756.